Skip to content
lifestyle.thedishh.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Tempest Therapeutics
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
May 29, 2026
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
May 6, 2026
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
May 5, 2026
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
May 4, 2026
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
May 3, 2026
Tempest Therapeutics Announces Up To $6 Million Private Placement
April 30, 2026
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
April 28, 2026
Tempest Reports Year End 2025 Financial Results and Provides Business Update
March 31, 2026
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
February 25, 2026
1
2
Next Page
→